Published on September 27, 2013 at 2:54 AM
For over a decade, the Sabin PDP, which is based at Texas Children's Hospital and Baylor College of Medicine in Houston, Texas, has been working on a human hookworm vaccine with the support of the Bill & Melinda Gates Foundation, Dutch Ministry of Foreign Affairs and Brazilian Ministry of Health. A hookworm vaccine has the potential to dramatically improve the health, economic, and social landscape in countries with high burdens of hookworm disease. As sponsor of the vaccine, the Sabin PDP will contribute to the HOOKVAC consortium by sharing the technology, research findings, and clinical trial results generated in previous studies, and will collaborate on the new clinical studies in Gabon.
"The Sabin PDP is excited to join with new partners from the European Union and Gabon to advance the development of a human hookworm vaccine," said Dr. Peter Hotez, director of the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development and founding dean of the National School of Tropical Medicine at Baylor College of Medicine. "By sharing the Sabin PDP's unique expertise in developing vaccines for NTDs with the HOOKVAC consortium, we intend to expand global knowledge of NTDs as well as benefit from the expertise of our new European and African partners to identify cutting edge ways to reduce the global burden of diseases affecting the world's poorest people."
The HOOKVAC consortium's key European partners include the Amsterdam Institute for Global Health and Development (AIGHD), Academic Medical Center, University of Amsterdam (AMC) and the Leiden University Medical Center (LUMC) in the Netherlands; Q-Biologicals in Belgium; University, Eberhard Karls University, T-bingen, Institute of Tropical Medicine, Center of Excellence Baden-W-rttemberg in Germany; Pharmidex in the UK; and the Centre de Recherches M-dicales de Lambar-n- of the Albert Schweitzer Hospital in Gabon. The key U.S. partners include the Sabin Vaccine Institute, Baylor College of Medicine and The George Washington University.
This press release reflects only the views of AIGHD and the Sabin Vaccine Institute. The European Union is not liable for any use that may be made of the information in this release.
Source: Sabin Vaccine Institute